CE
Bristol-Myers Squibb Company Ce
CELG-RI · NYSE
$0.12 +4.88% (+$0.01)
1M +19.10%
Market Cap $224.7M
P/E Ratio 0.03x
Div. Yield -
ROE 25.85%
Bulios Fair Price
$0.1
19.7% downside
Current Price
$0.12
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CELG-RI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
100 /100
Cheap P/S 0.00x
P/B 0.00x
P/FCF 0.01x
Growth
79 /100
Growing Rev. growth 20.86%
FCF growth 18.22%
Book val. growth 15.56%
Profitability
95 /100
Strong Net margin 14.64%
Op. margin 23.83%
FCF margin 31.75%
Quality
100 /100
Excellent ROE 25.85%
ROA 66.09%
Asset turnover 4.52x
Debt
46 /100
Moderate Current ratio -4.72x
Int. coverage 4.93x
Net debt/EBITDA -4.46x
Stability
19 /100
Unstable Rev. volatility 34.01%
EPS volatility 240.26%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CELG-RI
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Christopher S. Boerner
Employees
34,100
Headquarters
Princeton
Upcoming events
29 OCT
Earnings
Upcoming earnings report